Acquisition Announced
GSK acquisition of RAPT Therapeutics
US$2.2bn equity value
Announced 20 Jan 2026 · NASDAQ: RAPT · US$58.00 cash per share
Advisers
RAPT Therapeutics
Target
- Financial adviser
- Legal adviser
- Fairness opinion
- Target
- RAPT Therapeutics
- Acquirer
- GSK
- Target based in
- United States
- Buyer based in
- United Kingdom
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- argenx SE acquisition of Forte Biosciences Jul 2026 · US$2.2bn · Biotech
- UCB acquisition of Candid Therapeutics May 2026 · US$2.2bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Eli Lilly and Company acquisition of AtaiBeckley Jul 2026 · US$2.8bn · Biotech
Sources
- Jan 2026 Latham Advises on GSKs US2 2 Billion Acquisition of RAPT Therapeutics lw.com
- 20 Jan 2026 Target tender offer communication (SC14D9C), RAPT Therapeutics, Inc. sec.gov
- 20 Jan 2026 Press release (EX-99.1, exhibit), Stock-exchange announcement sec.gov
- 20 Jan 2026 GSK Agrees to Acquire RAPT Therapeutics for $2.2 Billion cooley.com
- 20 Jan 2026 Evercore: Advised GSK on its acquisition of RAPT Therapeutics evercore.com
- 2 Feb 2026 Tender offer statement (SC TO-T), RAPT Therapeutics, Inc. sec.gov
- 2 Feb 2026 Target response to tender offer (SC 14D9), RAPT Therapeutics, Inc. sec.gov



